IP Library Granted Patent US 9,655,981
Granted Patent B2
US 9,655,981 · App. 15/048,098 · Granted May 23, 2017

Mixed micelles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,981
App. No.
15/048,098
Granted
May 23, 2017
Kind
B2
Abstract

This disclosure is directed to mixed micelle compositions for administration of e.g., therapeutic agents or imaging agents to a subject.

Claims (11)

1. A method of delivering an imaging agent to a subject, the method comprising the step administering a mixed micelle comprising the imaging agent to the subject, wherein the mixed micelle comprises (a) a poly(ethylene oxide)-poly[(R)-3-hydroxybutyrate]-poly(ethylene oxide) (PEO-PHB-PEO) molecule synthesized from poly[(R)-3-hydroxybutyrate] diol with a molecular weight of about 2,300 Da and methoxy-poly(ethylene glycol) monocarboxylic acid having a molecular weight of about 4,900 Da and (b) a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) molecule having a molecular weight of about 12,600 wherein each PEO polymer block has about 100 PEO repeat units and the PPO polymer block has about 65 PPO repeat units, wherein the ratio of PEO-PHB-PEO to PEO-PPO-PEO is between about 7.7:3.3 and 6.3:2.7.

2. The method of claim 1 , wherein the imaging agent is a member selected from the group consisting of indocyanine green (ICG), gadolinium or manganese, iron oxide nanoparticles, quantum dots, iodine and barium.

3. The method of claim 2 , wherein the imaging agent is indocyanine green (ICG).

4. The method of claim 1 , wherein the imaging agent is more stable in the subject when administered in the mixed micelle, than when administered in an aqueous solution.

5. The method of claim 1 , wherein the subject has a tumor and the mixed micelle comprising the imaging agent is preferentially taken up by the tumor.

6. The method of claim 1 , further comprising a step of visualizing the imaging agent in the subject.

7. The method of claim 1 , wherein the size of the mixed micelle is between 10-120 nm.

8. The method of claim 1 , wherein the size of the mixed micelle is between 50-120 nm.

9. The method of claim 1 , wherein the size of the mixed micelle is about 110 nm.

10. The method of claim 1 , wherein the mixed micelle is a filamentous micelle.

11. The method of claim 1 , further comprising the step of adding the mixed micelle to a pharmaceutical carrier.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE BOX TITLED"THIS DOCUMENT SERVES AS AN OATH/DECLARATION (37 CFR 1.63)" WAS ERRONEOUSLY CHECKED AND THIS BOX SHOULD NOT HAVE BEEN CHECKED, PREVIOUSLY RECORDED AT REEL: 67607 FRAME: 108. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Dec 11, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 069715/0719 →
SECURITY INTEREST Recorded Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
SECURITY INTEREST Recorded Nov 7, 2016
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040575/0110 →